China Pediatric Pharmaceuticals applies for listing on NASDAQ

China Pediatric Pharmaceuticals, Inc. (OTC Bulletin Board: CPDU) ("China Pediatric Pharmaceuticals " or the "Company"), today announced it has applied for listing approval on the NASDAQ Capital Market (“NASDAQ”).

“This is an important milestone for China Pediatric Pharmaceuticals, and we are committed to working with NASDAQ to fulfill all of its listing requirements”

“This is an important milestone for China Pediatric Pharmaceuticals, and we are committed to working with NASDAQ to fulfill all of its listing requirements,” said Mr. Jun Xia, Chairman and Chief Executive Officer. “As a senior exchange NASDAQ is well suited for high-growth companies such as China Pediatric Pharmaceuticals that meet its stringent listing requirements. With a NASDAQ listing, our visibility will increase among investors who follow companies like ours, improving trading volume and liquidity. This should, in turn, attract new investors to our Company.”

The application is subject to review by NASDAQ's Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CPDU, until the Company is notified of its acceptance. CPDU believes it satisfies all of the listing qualifications associated with this application. We hope to receive approval to list on NASDAQ within two to three months.